-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Up to now, six batches of national centralized drug procurement have been carried out, and the average price of selected drugs has been reduced by more than half, covering various diseases such as hypertension, diabetes, and tumors
.
By the end of 2021, a total of 260 billion yuan in medical insurance and patient expenditures will be saved
.
On January 21, 2022, the release of the "Notice on Submitting the Purchase Data Related to the Scope of the Seventh Batch of Nationally Organized Centralized Drug Procurement" means that the seventh batch of centralized procurement has been started
.
The notice shows that before 24:00 on January 25th, all provinces will import management user accounts and medical institution accounts, and relevant users can enter the system through the account to conduct volume reporting operations; on January 26, volume reporting will be officially launched, and provinces will import 2021 historical purchases The volume data is for reference by medical institutions.
Medical institutions must fill in the relevant drug procurement requirements as required, and submit the data before 24:00 on February 16; before 17:00 on February 25, provinces need to complete the relevant drug procurement requirements.
work
.
So, what are the highlights of this batch of collections worthy of attention? The list shows that this batch of collection involves 58 varieties, covering tumor, diabetes, cardiovascular, nervous system and other therapeutic fields, among which there is no lack of metoprolol, omeprazole, cefix Oxime, metoprolol and other billion-dollar varieties are listed
.
Among them, meropenem is a synthetic broad-spectrum and potent carbapenem β-lactam antibiotic, which produces antibacterial effects by inhibiting the synthesis of bacterial cell walls
.
Meropenem for injection was developed by Sumitomo Dainippon Pharma Co.
, Ltd.
and entered the Chinese market in 1999
.
According to relevant data, the sales amount of meropenem for injection in China in 2020 was 5.
13 billion yuan
.
Omeprazole sodium is mainly used for the treatment of peptic ulcer bleeding and anastomotic ulcer bleeding; acute gastric mucosal damage complicated by stress state, acute gastric mucosal damage caused by non-steroidal anti-inflammatory drugs; prevention of severe diseases (such as brain bleeding, severe trauma, etc.
) stress state and upper gastrointestinal bleeding after gastric surgery
.
According to data from Minet.
com, in 2020, the sales of omeprazole sodium for injection in the terminals of public medical institutions nationwide will be 5 billion yuan.
.
Cefixime is an oral third-generation cephalosporin antibiotic.
According to Minet.
com data, in 2020, the market size of cefixime in public medical institutions in China will exceed 3 billion yuan, of which capsules account for about 26%
.
Metoprolol is a commonly used drug for chronic heart failure.
According to the data from Minet.
com, the sales of metoprolol preparations have gradually increased in China in recent years.
The total sales were 2.
734 billion yuan and 2.
966 billion yuan respectively
.
The competition on these tracks may be very fierce.
Take the large variety of cefixime with over 3 billion yuan as an example.
At present, the cefixime capsules of 8 domestic companies have passed the consistency evaluation, including Sinopharm Group, CSPC, Qilu Pharmaceutical, Beite Pharmaceuticals, Baiyunshan Pharmaceutical Factory, etc.
Among them, Better Pharmaceuticals was the first to review
.
The oral normal-release dosage form of cefixime is also on the list of the seventh batch of national purchases and reports, but the number of qualified enterprises has exceeded 10
.
Meropenem, a large variety of 5 billion yuan, currently has 10 companies with approval documents, of which 7 companies have passed the consistency evaluation, including Luoxin Pharmaceutical, Shenghuaxi Pharmaceutical, Peking University Pharmaceutical, Southern Pharmaceutical, CSPC Ouyi Pharmaceutical, Hanhui Pharmaceutical, Haibin Pharmaceutical,
etc.
The original research drug of Clindamycin Phosphate Injection has not yet been listed in China, but the competition in the generic drug market is fierce.
As of January 24, there are 12 companies including Chenxin Pharmaceutical, Luoxin Pharmaceutical, Xinhua Pharmaceutical, and North China Pharmaceutical.
The products passed/deemed to pass the consistency evaluation
.
In addition, the key monitoring catalogue "Edaravone" is also on the list this time
.
Data shows that in 2018, the sales of this product in public medical institutions across the country once exceeded 5 billion yuan
.
Up to now, there are 8 companies that have passed/deemed to have passed the evaluation of edaravone, including Simcere Pharmaceutical, Jilin Boda, Fujian Tianquan Pharmaceutical, Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical, Sinopharm Group Guorui Pharmaceutical , Kunming Jida Pharmaceutical, Chia Tai Fenghai Pharmaceutical, Qilu Pharmaceutical
.
.
By the end of 2021, a total of 260 billion yuan in medical insurance and patient expenditures will be saved
.
On January 21, 2022, the release of the "Notice on Submitting the Purchase Data Related to the Scope of the Seventh Batch of Nationally Organized Centralized Drug Procurement" means that the seventh batch of centralized procurement has been started
.
The notice shows that before 24:00 on January 25th, all provinces will import management user accounts and medical institution accounts, and relevant users can enter the system through the account to conduct volume reporting operations; on January 26, volume reporting will be officially launched, and provinces will import 2021 historical purchases The volume data is for reference by medical institutions.
Medical institutions must fill in the relevant drug procurement requirements as required, and submit the data before 24:00 on February 16; before 17:00 on February 25, provinces need to complete the relevant drug procurement requirements.
work
.
So, what are the highlights of this batch of collections worthy of attention? The list shows that this batch of collection involves 58 varieties, covering tumor, diabetes, cardiovascular, nervous system and other therapeutic fields, among which there is no lack of metoprolol, omeprazole, cefix Oxime, metoprolol and other billion-dollar varieties are listed
.
Among them, meropenem is a synthetic broad-spectrum and potent carbapenem β-lactam antibiotic, which produces antibacterial effects by inhibiting the synthesis of bacterial cell walls
.
Meropenem for injection was developed by Sumitomo Dainippon Pharma Co.
, Ltd.
and entered the Chinese market in 1999
.
According to relevant data, the sales amount of meropenem for injection in China in 2020 was 5.
13 billion yuan
.
Omeprazole sodium is mainly used for the treatment of peptic ulcer bleeding and anastomotic ulcer bleeding; acute gastric mucosal damage complicated by stress state, acute gastric mucosal damage caused by non-steroidal anti-inflammatory drugs; prevention of severe diseases (such as brain bleeding, severe trauma, etc.
) stress state and upper gastrointestinal bleeding after gastric surgery
.
According to data from Minet.
com, in 2020, the sales of omeprazole sodium for injection in the terminals of public medical institutions nationwide will be 5 billion yuan.
.
Cefixime is an oral third-generation cephalosporin antibiotic.
According to Minet.
com data, in 2020, the market size of cefixime in public medical institutions in China will exceed 3 billion yuan, of which capsules account for about 26%
.
Metoprolol is a commonly used drug for chronic heart failure.
According to the data from Minet.
com, the sales of metoprolol preparations have gradually increased in China in recent years.
The total sales were 2.
734 billion yuan and 2.
966 billion yuan respectively
.
The competition on these tracks may be very fierce.
Take the large variety of cefixime with over 3 billion yuan as an example.
At present, the cefixime capsules of 8 domestic companies have passed the consistency evaluation, including Sinopharm Group, CSPC, Qilu Pharmaceutical, Beite Pharmaceuticals, Baiyunshan Pharmaceutical Factory, etc.
Among them, Better Pharmaceuticals was the first to review
.
The oral normal-release dosage form of cefixime is also on the list of the seventh batch of national purchases and reports, but the number of qualified enterprises has exceeded 10
.
Meropenem, a large variety of 5 billion yuan, currently has 10 companies with approval documents, of which 7 companies have passed the consistency evaluation, including Luoxin Pharmaceutical, Shenghuaxi Pharmaceutical, Peking University Pharmaceutical, Southern Pharmaceutical, CSPC Ouyi Pharmaceutical, Hanhui Pharmaceutical, Haibin Pharmaceutical,
etc.
The original research drug of Clindamycin Phosphate Injection has not yet been listed in China, but the competition in the generic drug market is fierce.
As of January 24, there are 12 companies including Chenxin Pharmaceutical, Luoxin Pharmaceutical, Xinhua Pharmaceutical, and North China Pharmaceutical.
The products passed/deemed to pass the consistency evaluation
.
In addition, the key monitoring catalogue "Edaravone" is also on the list this time
.
Data shows that in 2018, the sales of this product in public medical institutions across the country once exceeded 5 billion yuan
.
Up to now, there are 8 companies that have passed/deemed to have passed the evaluation of edaravone, including Simcere Pharmaceutical, Jilin Boda, Fujian Tianquan Pharmaceutical, Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical, Sinopharm Group Guorui Pharmaceutical , Kunming Jida Pharmaceutical, Chia Tai Fenghai Pharmaceutical, Qilu Pharmaceutical
.
